Vertex Pharmaceuticals Incorporated VRTX reported second-quarter 2026 revenue of $3.3 billion, up 12.45% from a year earlier and slightly above Wall Street expectations. Gross profit rose to $2.8 billion, while operating profit increased to $1.2 billion, reflecting continued healthy profitability.
Net income attributable to common shareholders came in at $1.1 billion, with diluted earnings per share of $4.31. Cash from operating activities climbed to $1.4 billion, showing stronger cash generation during the quarter.
Vertex ended the period with $5.1 billion in cash and cash equivalents. Total liabilities were $7.2 billion, while capital spending on property and equipment remained modest at $133.4 million.
- Revenue: $3.3 billion, up 12.45% year over year
- Net income: $1.1 billion
- Diluted EPS: $4.31
- Operating cash flow: $1.4 billion
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Vertex Pharmaceuticals Incorporated Insider Trading Activity
Vertex Pharmaceuticals Incorporated insiders have traded $VRTX stock on the open market 50 times in the past 6 months. Of those trades, 0 have been purchases and 50 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by insiders over the last 6 months:
- AMIT SACHDEV (EVP Chief Patient & Ext Af Off) has made 0 purchases and 9 sales selling 60,459 shares for an estimated $28,377,385.
- CARMEN BOZIC (EVP and CMO) has made 0 purchases and 7 sales selling 19,069 shares for an estimated $8,685,637.
- DUNCAN MCKECHNIE (EVP, Chief Commercial Officer) has made 0 purchases and 5 sales selling 11,521 shares for an estimated $5,664,789.
- JONATHAN BILLER (EVP and Chief Legal Officer) has made 0 purchases and 5 sales selling 7,578 shares for an estimated $3,640,101.
- MARK E. BUNNAGE (EVP, Chief Scientific Officer) has made 0 purchases and 4 sales selling 6,260 shares for an estimated $2,984,769.
- EDWARD MORROW III ATKINSON (EVP, Chief Technical Ops. Off.) has made 0 purchases and 4 sales selling 5,267 shares for an estimated $2,512,184.
- OURANIA TATSIS (EVP, Chief Reg. & Quality Off.) has made 0 purchases and 6 sales selling 4,703 shares for an estimated $2,350,876.
- JOY LIU (EVP and Chief Legal Officer) has made 0 purchases and 5 sales selling 4,630 shares for an estimated $2,131,396.
- KRISTEN AMBROSE (SVP & Chief Accounting Officer) has made 0 purchases and 3 sales selling 1,956 shares for an estimated $914,567.
- SANGEETA N. BHATIA has made 0 purchases and 2 sales selling 584 shares for an estimated $267,746.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Vertex Pharmaceuticals Incorporated Hedge Fund Activity
We have seen 789 institutional investors add shares of Vertex Pharmaceuticals Incorporated stock to their portfolio, and 699 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL RESEARCH GLOBAL INVESTORS added 3,809,620 shares (+22.0%) to their portfolio in Q1 2026, for an estimated $1,692,499,877
- WINSLOW CAPITAL MANAGEMENT, LLC removed 887,640 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $394,351,822
- GOLDMAN SACHS GROUP INC added 664,473 shares (+37.9%) to their portfolio in Q1 2026, for an estimated $295,205,419
- WELLINGTON MANAGEMENT GROUP LLP removed 609,142 shares (-15.9%) from their portfolio in Q1 2026, for an estimated $270,623,516
- ALLIANCEBERNSTEIN L.P. removed 585,696 shares (-13.0%) from their portfolio in Q1 2026, for an estimated $260,207,161
- PRICE T ROWE ASSOCIATES INC /MD/ removed 518,836 shares (-22.8%) from their portfolio in Q1 2026, for an estimated $230,503,269
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN removed 439,260 shares (-54.6%) from their portfolio in Q1 2026, for an estimated $195,150,040
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Vertex Pharmaceuticals Incorporated Congressional Stock Trading
Members of Congress have traded $VRTX stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by members of Congress over the last 6 months:
- SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Vertex Pharmaceuticals Incorporated Analyst Ratings
Wall Street analysts have issued reports on $VRTX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Maxim Group issued a "Buy" rating on 03/18/2026
- HC Wainwright & Co. issued a "Buy" rating on 02/13/2026
To track analyst ratings and price targets for Vertex Pharmaceuticals Incorporated, check out Quiver Quantitative's $VRTX forecast page.
Vertex Pharmaceuticals Incorporated Price Targets
Multiple analysts have issued price targets for $VRTX recently. We have seen 15 analysts offer price targets for $VRTX in the last 6 months, with a median target of $575.0.
Here are some recent targets:
- Brian Skorney from Baird set a target price of $350.0 on 07/07/2026
- Brian Abrahams from RBC Capital set a target price of $570.0 on 07/07/2026
- Eliana Merle from Barclays set a target price of $615.0 on 05/06/2026
- Terence Flynn from Morgan Stanley set a target price of $616.0 on 05/05/2026
- William Pickering from Bernstein set a target price of $572.0 on 05/05/2026
- Whitney Ijem from Canaccord Genuity set a target price of $436.0 on 05/05/2026
- Naz Rahman from Maxim Group set a target price of $575.0 on 03/18/2026
